ERIS Lifesciences board approves acquisition of balance 30% stake in Swiss Parenterals



Further, the board has approved the issuance of up to 23,06,372 equity
shares of the Company on preferential basis to discharge the consideration for acquisition of 30% stake in Swiss Parenterals.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *